# Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial

> **NCT02699645** · PHASE3 · COMPLETED · sponsor: **The George Institute** · enrollment: 1671 (actual)

## Conditions studied

- Intracerebral Haemorrhage (ICH)
- Hypertension

## Interventions

- **DRUG:** telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02699645
- **Lead sponsor:** The George Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-28
- **Primary completion:** 2025-08-27
- **Final completion:** 2025-08-27
- **Target enrollment:** 1671 (ACTUAL)
- **Last updated:** 2025-09-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02699645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02699645, "Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02699645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*